Coronary heart disease events in the Women's Health Initiative hormone trials: Effect modification by metabolic syndrome: A nested case-control study within the Women's Health Initiative randomized clinical trials

Menopause

Volumn 20, Issue 3, 2013, Pages 254-260

  Wild, Robert A ^a   Wu, Chunyuan ^b   Curb, J D ^c   Martin, Lisa W ^d   Phillips, Lawrence ^e   Stefanick, Marcia ^f   Trevisan, Maurizio ^g   Manson, Joann E ^h  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e EMORY UNIVERSITY   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Health Sciences System   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Coronary heart disease; Effect modification; Hormone therapy; Metabolic syndrome; Women's Health Initiative

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CASE CONTROL STUDY; CHI SQUARE TEST; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; ESTROGEN THERAPY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYSTERECTOMY; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; STATISTICAL SIGNIFICANCE; STUDENT T TEST; WOMEN'S HEALTH;

EID: 85027923654     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e31826f80e0     Document Type: Article

References (15)

1. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297: 1465-1477.
2. Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the Women's Health Initiative trials of hormone therapy. Arch Intern Med 2008; 168: 2245-2253.
3. Bray PF, Larson JC, LaCroix AZ, et al. Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events. Am J Cardiol 2008;101: 1599-1605.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-333.
5. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial 6. JAMA 2004; 291: 1701-1712.
6. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19: 61-109.
7. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement Circulation 2005;112: 2735-2752.
8. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative hormone trial Diabetologia 2004;47: 1175-1187.
9. Festa A, Williams K, Hanley AJ, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 2005;111: 3465-3472.
10. Kim HC, Greenland P, Rossouw JE, et al. Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol 2010;55: 2080-2091.
11. Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009;42: 1331-1346.
12. Hsia J, Otvos JD, Rossouw JE, et al. Lipoprotein particle concentrations may explain the absence of coronary protection in the Women's Health Initiative hormone trials. Arterioscler Thromb Vasc Biol 2008;28: 1666-1671.
13. Gazi I, Tsimihodimos V, Filippatos T, Bairaktari E, Tselepis AD, Elisaf M. Concentration and relative distribution of low-density lipoprotein subfractions in patients with metabolic syndrome defined according to the National Cholesterol Education Program criteria. Metabolism 2006; 55: 885-891.
14. Sternfeld B, Wang H, Quesenberry CP Jr, et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. Am J Epidemiol 2004;160: 912-922.
15. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US officeYbased physicians, 2000-2009. Menopause 2011;18: 385-392.